PPAR-y2 and PTPRD gene polymorphisms influence type 2 diabetes patients' response to pioglitazone in China
Aim: To investigate the influence of peroxisome proliferator-activated receptor y2 (PPAR-y2) gene polymorphism rs1801282 and protein tyrosine phosphatase receptor type D (PTPRD) gene polymorphism rs17584499 on the occurrence of type 2 diabetes and pioglitazone efficacy in a Chinese Han population. M...
Saved in:
Published in | 中国药理学报:英文版 no. 2; pp. 255 - 261 |
---|---|
Main Author | |
Format | Journal Article |
Language | English |
Published |
2013
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Aim: To investigate the influence of peroxisome proliferator-activated receptor y2 (PPAR-y2) gene polymorphism rs1801282 and protein tyrosine phosphatase receptor type D (PTPRD) gene polymorphism rs17584499 on the occurrence of type 2 diabetes and pioglitazone efficacy in a Chinese Han population. Methods: One hundred ninety seven type 2 diabetes patients and 212 healthy controls were enrolled. Among them, 67 type 2 diabetes patients were administered pioglitazone (30 mg/d, po) for 3 months. All the subjects were genotyped for genetic variants in PPAR-~2 and PTPRD using MALDI-TOF mass spectrometry. Fasting plasma glucose, postprandial plasma glucose, glycated hemoglobin, serum triglyceride, total cholesterol, low-density and high-density lipoprotein-cholesterol were determined. Results: The PPAR-y2 gene rs1801282 polymorphism was significantly associated with type 2 diabetes susceptibility (0R=0.515, 95% Cl 0.268-0.990) and the PTPRD gene rs17584499 polymorphism was also significantly associated with type 2 diabetes (0R=1.984, 95% Cl 1.135-3.469) in a dominant model adjusted for age, gender and BMI. After pioglitazone treatment for 3 months, the type 2 diabetes patients with PPAR-y2 rs1801282 CG genotypes significantly showed higher differential values of postprandial plasma glucose and serum triglyceride compared with those with rs1801282 CC genotype. The patients with PTPRD rs17584499 CT+TT genotypes showed significantly lower differential value of postprandial plasma glucose compared to those with rs17584499 CC genotype. Conclusion: Diabetes risk alleles in PPAR-y2 (rs1801282) and PTPRD (rs17584499) are associated with pioglitazone therapeutic efficacy. |
---|---|
AbstractList | Aim: To investigate the influence of peroxisome proliferator-activated receptor y2 (PPAR-y2) gene polymorphism rs1801282 and protein tyrosine phosphatase receptor type D (PTPRD) gene polymorphism rs17584499 on the occurrence of type 2 diabetes and pioglitazone efficacy in a Chinese Han population. Methods: One hundred ninety seven type 2 diabetes patients and 212 healthy controls were enrolled. Among them, 67 type 2 diabetes patients were administered pioglitazone (30 mg/d, po) for 3 months. All the subjects were genotyped for genetic variants in PPAR-~2 and PTPRD using MALDI-TOF mass spectrometry. Fasting plasma glucose, postprandial plasma glucose, glycated hemoglobin, serum triglyceride, total cholesterol, low-density and high-density lipoprotein-cholesterol were determined. Results: The PPAR-y2 gene rs1801282 polymorphism was significantly associated with type 2 diabetes susceptibility (0R=0.515, 95% Cl 0.268-0.990) and the PTPRD gene rs17584499 polymorphism was also significantly associated with type 2 diabetes (0R=1.984, 95% Cl 1.135-3.469) in a dominant model adjusted for age, gender and BMI. After pioglitazone treatment for 3 months, the type 2 diabetes patients with PPAR-y2 rs1801282 CG genotypes significantly showed higher differential values of postprandial plasma glucose and serum triglyceride compared with those with rs1801282 CC genotype. The patients with PTPRD rs17584499 CT+TT genotypes showed significantly lower differential value of postprandial plasma glucose compared to those with rs17584499 CC genotype. Conclusion: Diabetes risk alleles in PPAR-y2 (rs1801282) and PTPRD (rs17584499) are associated with pioglitazone therapeutic efficacy. |
Author | Qi PEI Qiong HUANG Guo-ping YANGI Ying-chun ZHAO Ji-ye YIN Min SONG Yi ZHENG Zhao-hui MO Hong-hao ZHOU Zhao-qian LIU |
AuthorAffiliation | Institute of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, Central South University, Changsha 41007~,Chinat Department of Pharmacy, Third Xiangya Hospital, Central South University, Changsha 410013, China; Institute of ClinicalPharmacology, Anhui Medical University, Hefei 230032, China; Center of Clinical Pharmacology, Third Xiangya Hospital, Central SouthUniversity, Changsha 410013, China; Osteooorosis Research Center. CreiEhton University, Omaha, NE 68131, USA Department ofEndocrinology, Third Xiangya Hospital, Central South University, Changsha 410013, China |
Author_xml | – sequence: 1 fullname: Qi PEI Qiong HUANG Guo-ping YANGI Ying-chun ZHAO Ji-ye YIN Min SONG Yi ZHENG Zhao-hui MO Hong-hao ZHOU Zhao-qian LIU |
BookMark | eNqNjkFuwjAQRS1EpULLHaYHiBTHpkmXFW3FMkLskYEhGeSMTcZdpBfopXqnXoEsOACr9xfvS2-uphwYJ2qmS7vMymJpp-N-LXVm88o8qrnIOc9NYfTbTPm6ft9kQwGOj1Bv680HNMgIMfihC31sSToB4pP_Rj4gpCEiFHAkt8eEAtElQk7y__cLPUoMLKMUIFJoPCX3M6aMd1i1xO5ZPZycF1zc-KRevj63q3V2aAM3F-JmF3vqXD_srK0qU2lt7nGuGABLkA |
ContentType | Journal Article |
DBID | 2RA 92L CQIGP W91 ~WA |
DatabaseName | 维普_期刊 中文科技期刊数据库-CALIS站点 维普中文期刊数据库 中文科技期刊数据库-医药卫生 中文科技期刊数据库- 镜像站点 |
DatabaseTitleList | |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology |
DocumentTitleAlternate | PPAR-y2 and PTPRD gene polymorphisms influence type 2 diabetes patients' response to pioglitazone in China |
EISSN | 1745-7254 |
EndPage | 261 |
ExternalDocumentID | 44883811 |
GroupedDBID | --- -05 -0E -Q- -S~ .3N 0R~ 188 1OC 23M 2RA 2WC 31~ 36B 3V. 4.4 406 53G 5GY 5VR 5VS 6J9 70F 7X7 8-1 88E 8FI 8FJ 8R4 8R5 8RM 92L 92M 9D9 9DE A8Z AADWK AANZL AATNV AAWBL AAYFA AAYJO AAZLF ABAWZ ABGIJ ABKZE ABUWG ACAOD ACBMV ACBRV ACBYP ACGFO ACGFS ACIGE ACIWK ACKTT ACPRK ACRQY ACTTH ACVWB ACXQS ACZOJ ADBBV ADFRT ADHDB ADMDM ADQMX ADRAZ ADYYL AEDAW AEFTE AEJRE AENEX AESKC AEVLU AEXYK AFBPY AFKRA AFNRJ AFRAH AFSHS AFUIB AFZJQ AGAYW AGEZK AGGBP AGHAI AHMBA AHSBF AILAN AJAOE AJCLW AJDOV AJRNO ALFFA ALMA_UNASSIGNED_HOLDINGS AMRJV AMYLF AOIJS AXYYD BAWUL BBNVY BENPR BFHJK BHPHI BKKNO BPHCQ BVXVI C1A CAG CAJEE CAJUS CCEZO CCPQU CHBEP CIEJG CO8 COF CQIGP CS3 CW9 DIK DNIVK DPUIP E3Z EBLON EBS EE. EIOEI EJD EMB EMOBN ESTFP F5P FA0 FDQFY FERAY FIZPM FSGXE FYUFA GX1 HCIFZ HH5 HMCUK HYE HZI HZ~ IWAJR JSO JUIAU JZLTJ K97 KQ8 LH4 LW6 M1P M48 M7P MK0 NQJWS NXXTH NYICJ O9- OK1 OVD P2P P6G PQQKQ PROAC PSQYO Q-- Q-4 Q2X R-E RNT RNTTT RPM RT5 S.. SNX SNYQT SOHCF SRMVM SV3 SWTZT T8U TAOOD TBHMF TDRGL TEORI TR2 TSG U1F U1G U5E U5O UKHRP UZ5 W91 ~88 ~NG ~WA |
ID | FETCH-chongqing_primary_448838113 |
ISSN | 1671-4083 |
IngestDate | Wed Feb 14 10:43:55 EST 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 2 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-chongqing_primary_448838113 |
Notes | pioglitazone; type 2 diabetes; PPAR-y2 rs1801282; PTPRD rs17584499; genetic polymorphisms; Chinese Han population Aim: To investigate the influence of peroxisome proliferator-activated receptor y2 (PPAR-y2) gene polymorphism rs1801282 and protein tyrosine phosphatase receptor type D (PTPRD) gene polymorphism rs17584499 on the occurrence of type 2 diabetes and pioglitazone efficacy in a Chinese Han population. Methods: One hundred ninety seven type 2 diabetes patients and 212 healthy controls were enrolled. Among them, 67 type 2 diabetes patients were administered pioglitazone (30 mg/d, po) for 3 months. All the subjects were genotyped for genetic variants in PPAR-~2 and PTPRD using MALDI-TOF mass spectrometry. Fasting plasma glucose, postprandial plasma glucose, glycated hemoglobin, serum triglyceride, total cholesterol, low-density and high-density lipoprotein-cholesterol were determined. Results: The PPAR-y2 gene rs1801282 polymorphism was significantly associated with type 2 diabetes susceptibility (0R=0.515, 95% Cl 0.268-0.990) and the PTPRD gene rs17584499 polymorphism was also significantly associated with type 2 diabetes (0R=1.984, 95% Cl 1.135-3.469) in a dominant model adjusted for age, gender and BMI. After pioglitazone treatment for 3 months, the type 2 diabetes patients with PPAR-y2 rs1801282 CG genotypes significantly showed higher differential values of postprandial plasma glucose and serum triglyceride compared with those with rs1801282 CC genotype. The patients with PTPRD rs17584499 CT+TT genotypes showed significantly lower differential value of postprandial plasma glucose compared to those with rs17584499 CC genotype. Conclusion: Diabetes risk alleles in PPAR-y2 (rs1801282) and PTPRD (rs17584499) are associated with pioglitazone therapeutic efficacy. 31-1347/R |
ParticipantIDs | chongqing_primary_44883811 |
PublicationCentury | 2000 |
PublicationDate | 2013 |
PublicationDateYYYYMMDD | 2013-01-01 |
PublicationDate_xml | – year: 2013 text: 2013 |
PublicationDecade | 2010 |
PublicationTitle | 中国药理学报:英文版 |
PublicationTitleAlternate | Acta Pharmacologica Sinica |
PublicationYear | 2013 |
SSID | ssj0032319 |
Score | 4.034827 |
Snippet | Aim: To investigate the influence of peroxisome proliferator-activated receptor y2 (PPAR-y2) gene polymorphism rs1801282 and protein tyrosine phosphatase... |
SourceID | chongqing |
SourceType | Publisher |
StartPage | 255 |
SubjectTerms | 2型糖尿病 MALDI-TOF质谱分析 中国汉族人群 吡格列酮 基因多态性 患者 过氧化物酶体增殖物激活受体 高密度脂蛋白胆固醇 |
Title | PPAR-y2 and PTPRD gene polymorphisms influence type 2 diabetes patients' response to pioglitazone in China |
URI | http://lib.cqvip.com/qk/95561A/201302/44883811.html |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3dbtMwFLaqXXGDYIBgMGQkvBvPU5smjn3pbqnSia4ZtNK6m6nJUhoJmm1tLroX4CF4Fd6JV-DYTrLwK-Amcnxi5-d8cs9xz_kOQq8lmPHduc-ZFInLXM49FjuiwzjYCu00AZPARFUOT3g4cY_PvLNW63MjaqlYxwfJ7S_zSv5Hq9AHetVZsv-g2XpS6IA26BeOoGE4_pWOo0i9ZRvHRvyPI3Dn4NJUF14Ajx4-YLb6aMKtbBmSn7ZbS07VFQn6pHdIhE9vbMSsKadxleXvNYP3bW6JRepK25UtSwKX9ARRRyTwiOyRHjQEEUdE9UngE9kmgmsRXKCgwYlQRHnlzaQyF8OojhZJkPp6lJBE1NG1pxmNggE9zXRBpHCidJpAkTOT4jWFswGdQpMli2JJz0M1oscZ26R0OjihQ3jidyMYMM1AFEDjfDHL2aLI6HBEQ5iQwTmIRhMrudYr3ZvBpLkNYvNXyzWb-9oNtvVwDlLb57u6Sq_lpy4h7DTXacsNXP7kO5YP_gfibXBcBdgzhhmh7eo1dOjW_1B1wS7WrlV9c83NsYCHv4b3blgo4wfofulaYGVx8hC10uU22ossN_lmH4_vUu1W-3gPR3es5ZtH6EMJJgxgwgZMWIMJfwcmXIMJazBhB1dgwhWYvn75hCsY4XWOmzCC4djA6DF61Q_GhyGrX-biytKeXFTfo_sEbS1hzFOEhYyl6Pj8MrmcuR05n6WpN5914thNhceT7jO08_t5dv4kfI7uOabwiN7seoG21jdFugvm3zp-afTwDUQqWSQ |
link.rule.ids | 315,786,790,4043 |
linkProvider | Scholars Portal |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=PPAR-y2+and+PTPRD+gene+polymorphisms+influence+type+2+diabetes+patients%EF%BC%87+response+to+pioglitazone+in+China&rft.jtitle=%E4%B8%AD%E5%9B%BD%E8%8D%AF%E7%90%86%E5%AD%A6%E6%8A%A5%EF%BC%9A%E8%8B%B1%E6%96%87%E7%89%88&rft.au=Qi+PEI+Qiong+HUANG+Guo-ping+YANGI+Ying-chun+ZHAO+Ji-ye+YIN+Min+SONG+Yi+ZHENG+Zhao-hui+MO+Hong-hao+ZHOU+Zhao-qian+LIU&rft.date=2013&rft.issn=1671-4083&rft.eissn=1745-7254&rft.issue=2&rft.spage=255&rft.epage=261&rft.externalDocID=44883811 |
thumbnail_s | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fimage.cqvip.com%2Fvip1000%2Fqk%2F95561A%2F95561A.jpg |